Carcinoma, Non-Small-Cell Lung  >>  linsitinib (ASP7487)  >>  Phase 2
Welcome,         Profile    Billing    Logout  

2 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
linsitinib (ASP7487) / Sling Therap
NCT01221077: Study of Erlotinib (Tarceva®) in Combination With OSI-906 in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) With Activating Mutations of the Epidermal Growth Factor Receptor (EGFR) Gene

Completed
2
88
Canada, US, RoW
OSI-906, Erlotinib, OSI-774, Tarceva, Placebo
Astellas Pharma Inc
NSCLC, Non Small Cell Lung Cancer
03/13
09/14
NCT01186861 / 2010-020916-12: Phase 2 Study of Maintenance OSI-906 Plus Erlotinib (Tarceva®), or Placebo Plus Erlotinib in Patients With Nonprogression Following 4 Cycles of Platinum-based Chemotherapy

Completed
2
205
Canada, US, Europe, RoW
OSI-906, erlotinib, OSI-774, Tarceva, placebo
Astellas Pharma Inc
Non-Small Cell Lung Cancer (NSCLC) With Nonprogression Following 4 Cycles of Platinum-based Chemotherapy
07/13
03/15

Download Options